Inventiva reports its 2022 first-half financial results and

Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from...

Related Keywords

New York ,United States ,Daix ,Bourgogne ,France ,Paris ,France General ,United Kingdom ,Washington ,China ,Boston ,Massachusetts ,Russia ,London ,City Of ,Ukraine ,Netherlands ,Belgium ,Champagne Ardenne ,Tianqing ,Zhejiang ,French ,Sino Biopharm ,Pascaline Clerc ,Patricial Bank ,Brunswick Group ,Exchange Commission On ,Chia Tai Tianqing Pharmaceutical Group ,University Of Florida ,Nasdaq ,Market Program ,Global External Affairs ,French Research ,Abbvie Inc ,European Investment Bank ,Company Phase ,Drug Development Summit ,Exchange Commission ,Euronext ,Long Island City ,Euronext Paris ,Chief Executive Officer ,Legend Phase ,At The Market Program ,French State ,Agricole Champagne Bourgogne ,Half Year Financial Report ,Non Alcoholic Fatty Liver Disease ,Professor Cusi ,Investigational New Drug ,Greater China ,Euronext Tech Leaders ,Patient First Visit ,Nantucket Therapeutics Conference ,Tech Innovation Days ,Healthcare Conference ,Liver Meeting ,Development Summit ,Nasdaq Global Market ,Global External ,Roquet Montegon ,Private Securities Litigation Reform Act ,Universal Registration Document ,Des March ,Annual Report ,Paris Stock Exchange Iva ,Inventiva ,